• SPX
  • $5,948.71
  • 0.53 %
  • $31.60
  • DJI
  • $43,870.35
  • 1.06 %
  • $461.88
  • N225
  • $38,415.32
  • 1.02 %
  • $389.15
  • FTSE
  • $8,149.27
  • 0.79 %
  • $64.20
  • IXIC
  • $18,972.42
  • 0.03 %
  • $6.28
Becton, Dickinson and Company (BDXB) Stock Price, News & Analysis

Becton, Dickinson and Company (BDXB) Stock Price, News & Analysis

Currency in USD Disclaimer

NA

NA

NA

Day's range
$47.65
Day's range
$48.82
50-day range
$47.16
Day's range
$50.65
  • Country: US
  • ISIN: US0758874061
52 wk range
$45.85
Day's range
$52.52
  • CEO: Mr. Thomas E. Polen Jr.
  • Website: Visit Site
Notice: This company has been marked as potentially delisted and may not be actively trading.


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 1.14
  • Piotroski Score 8.00
  • Grade Overweight
  • Symbol (BDXB)
  • Company Becton, Dickinson and Company
  • Price $48.16
  • Changes Percentage (1.39%)
  • Change $0.66
  • Day Low $47.65
  • Day High $48.82
  • Year High $52.52

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

  • Last Earnings 01/12/2023
  • Ex-Dividend for 5/16 Dividend 02/14/2023
  • Dividend Payable 03/01/2023
  • Today N/A
  • Next Earnings (Estimated) 08/06/2020
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Buy
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) $6.33
  • Trailing P/E Ratio 7.6034101673508
  • Forward P/E Ratio 7.6034101673508
  • P/E Growth 7.6034101673508
  • Net Income $1.73 B

Income Statement

Quarterly

Annual

Latest News of BDXB

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Becton, Dickinson and Company Frequently Asked Questions

  • What were the earnings of BDXB in the last quarter?

    In the last quarter Becton, Dickinson and Company earnings were on Thursday, August, 6th. The Becton, Dickinson and Company maker reported $2.20 EPS for the quarter, beating analysts' consensus estimates of $2.04 by $0.16.

  • What is the Becton, Dickinson and Company stock price today?

    Today's price of Becton, Dickinson and Company is $48.16 — it has increased by +1.39% in the past 24 hours. Watch Becton, Dickinson and Company stock price performance more closely on the chart.

  • Does Becton, Dickinson and Company release reports?

    Yes, you can track Becton, Dickinson and Company's financials in yearly and quarterly reports directly on Stocks.News.

  • What is the Becton, Dickinson and Company stock forecast?

    Watch the Becton, Dickinson and Company chart and read a more detailed Becton, Dickinson and Company stock forecast to see what analysts suggest you do with its shares.

  • What is Becton, Dickinson and Company stock ticker?

    The stock ticker can vary on the respective exchange. For instance, on NYSE, exchange stock trades by Becton, Dickinson and Company stock ticker.

  • How to buy Becton, Dickinson and Company stocks?

    Like other stocks, BDXB shares are sold on stock exchanges such as NYSE. The best way to obtain them is through an online stock broker. Open an account, follow the broker's steps, and start trading.

  • What is Becton, Dickinson and Company's EBITDA?

    Becton, Dickinson and Company measures a company's operating performance, and its growth indicates efficiency improvements. Access more stats in Becton, Dickinson and Company’s financial statements.

  • What is the Becton, Dickinson and Company's net income ratio for the financial year 2024?

    The net income ratio for the financial year 2024 is 0.0855387055, which equates to approximately 8.55%. This ratio indicates the percentage of net income generated from total revenue and serves as a key measure of a company’s profitability.

  • Should I invest in Becton, Dickinson and Company stocks?

    Investing in stocks requires thorough research. Carefully examine all available data, including Becton, Dickinson and Company's financials relevant news, and technical analysis. Becton, Dickinson and Company's technical analysis shows a “buy” rating today and a one-week “buy” rating. Since market conditions can change, it’s wise to look at longer-term trends — the one-month rating for Becton, Dickinson and Company stock currently indicates a “sell” signal. For more insights, review Becton, Dickinson and Company’s technical analysis.

  • A revenue figure for Becton, Dickinson and Company for its last quarter?

    Becton, Dickinson and Company published it's last quarterly revenues at $5.44 B.

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.